Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Leiner

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

To launch private-label equivalent of Tums Ultra Strength tablets in SKUs of 36 and 72 in December under its Pharmacist Formula control brand. Also in December, the company will introduce 500 mg acetaminophen (72- and 100-count SKUs) and 200 mg ibuprofen (72- and 100-count SKUs) in senior-friendly Kwik Kap packaging. Leiner will add a private-label version of P&G's DayQuil sinus & congestion caplets (12 count) in January 1995 to its recently launched equivalent of DayQuil sinus & pain caplets (20 count). The company will debut a version of P&G's Vicks children's chewable DayQuil allergy in four-ounce bottles in January. In February, Leiner will launch a copy of Benadryl cold/allergy caplets (20 and 40 count) and a version of P&G's Pepto-Bismol caplets (40 count). Expected in December 1995 is Leiner's version of Kaopectate IB caplets in 6- and 12-count SKUs

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS083476

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By